Browse > Article
http://dx.doi.org/10.5352/JLS.2011.21.5.631

Analysis of Global Gene Expression Profile of Human Adipose Tissue Derived Mesenchymal Stem Cell Cultured with Cancer Cells  

Kim, Jong-Myung (School of Medicine, Pusan National University)
Yu, Ji-Min (Department of Physiology, School of Medicine, Pusan National University)
Bae, Yong-Chan (Department of Plastic Surgery, School of Medicine, Pusan National University)
Jung, Jin-Sup (Department of Physiology, School of Medicine, Pusan National University)
Publication Information
Journal of Life Science / v.21, no.5, 2011 , pp. 631-646 More about this Journal
Abstract
Mesenchymal stem cells (MSC) are multipotent and can be isolated from diverse human tissues including bone marrow, fat, placenta, dental pulp, synovium, tonsil, and the thymus. They function as regulators of tissue homeostasis. Because of their various advantages such as plasticity, easy isolation and manipulation, chemotaxis to cancer, and immune regulatory function, MSCs have been considered to be a potent cell source for regenerative medicine, cancer treatment and other cell based therapy such as GVHD. However, relating to its supportive feature for surrounding cell and tissue, it has been frequently reported that MSCs accelerate tumor growth by modulating cancer microenvironment through promoting angiogenesis, secreting growth factors, and suppressing anti-tumorigenic immune reaction. Thus, clinical application of MSCs has been limited. To understand the underlying mechanism which modulates MSCs to function as tumor supportive cells, we co-cultured human adipose tissue derived mesenchymal stem cells (ASC) with cancer cell lines H460 and U87MG. Then, expression data of ASCs co-cultured with cancer cells and cultured alone were obtained via microarray. Comparative expression analysis was carried out using DAVID (Database for Annotation, Visualization and Integrated Discovery) and PANTHER (Protein ANalysis THrough Evolutionary Relationships) in divers aspects including biological process, molecular function, cellular component, protein class, disease, tissue expression, and signal pathway. We found that cancer cells alter the expression profile of MSCs to cancer associated fibroblast like cells by modulating its energy metabolism, stemness, cell structure components, and paracrine effect in a variety of levels. These findings will improve the clinical efficacy and safety of MSCs based cell therapy.
Keywords
Mesenchymal stem cell (MSC); cancer; MSC-cancer interaction; comparative expression analysis; cancer associated fibroblast;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Studeny, M., F. C. Marini, R. E. Champlin, C. Zompetta, I. J. Fidler, and M. Andreeff. 2002. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 62, 3603-3608.
2 Thomas, D. A. and J. Massagué. 2005. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380.   DOI
3 Valtieri, M. and A. Sorrentino. 2008. The mesenchymal stromal cell contribution to homeostasis. J. Cell Physiol. 217, 296-300.   DOI
4 Wahl, S. M. and W. Chen. 2005. Transforming growth factor- beta-induced regulatory T cells referee inflammatory and autoimmune diseases. Arthritis Res. Ther. 7, 62-68.   DOI
5 Weigert, A., D. Sekar, and B. Brüne. 2009. Tumor-associated macrophages as targets for tumor immunotherapy. Immunotherapy 1, 83-95.   DOI
6 Xing, F., J. Saidou, and K. Watabe. 2010. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci. 15, 166-179.   DOI
7 Yu, J. M., E. S. Jun, Y. C. Bae, and J. S. Jung. 2008. Mesenchymal stem cells derived from human adipose tissues favor tumor cell growth in vivo. Stem Cells Dev. 17, 463-473.   DOI
8 Picinich, S. C., P. J. Mishra, P. J. Mishra, J. Glod, and D. Banerjee. 2007. The therapeutic potential of mesenchymal stem cells. Cell- & tissue-based therapy. Expert. Opin. Biol. Ther. 7, 965-973.   DOI
9 Pittenger, M. F., A. M. Mackay, S. C. Beck, R. K. Jaiswal, R. Douglas, J. D. Mosca, M. A. Moorman, D. W. Simonetti, S. Craig, and D. R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147.   DOI
10 Rathinam, R. and S. K. Alahari. 2010. Important role of integrins in the cancer biology. Cancer Metastasis Rev. 29, 223-237.   DOI
11 Rozen, N., S. Ish-Shalom, A. Rachmiel, H. Stein, and D. Lewinson. 2000. Interleukin-6 modulates trabecular and endochondral bone turnover in the nude mouse by stimulating osteoclast differentiation. Bone 26, 469-474.   DOI
12 Russell, S. T. and M. J. Tisdale. 2002. Effect of a tumour- derived lipid-mobilising factor on glucose and lipid metabolism in vivo. Br. J. Cancer 87, 580-584.   DOI
13 Safford, K. M., K. C. Hicok, S. D. Safford, Y. D. Halvorsen, W. O. Wilkison, J. M. Gimble, and H. E. Rice. 2002. Neurogenic differentiation of murine and human adipose- derived stromal cells. Biochem. Biophys. Res. Commun. 294, 371-379.   DOI
14 Salazar, L. M. and A. M. Herrera. 2011. Fibrotic response of tissue remodeling in COPD. Lung [Epub ahead of print].
15 Semba, S., Y. Kodama, K. Ohnuma, E. Mizuuchi, R. Masuda, M. Yashiro, K. Hirakawa, and H. Yokozaki. 2009. Direct cancer- stromal interaction increases fibroblast proliferation and enhances invasive properties of scirrhous-type gastric carcinoma cells. Br. J. Cancer 101, 1365-1373.   DOI   ScienceOn
16 Loffler, D., K. Brocke-Heidrich, G. Pfeifer, C. Stocsits, J.Hackermüller, A. K. Kretzschmar, R. Burger, M. Gramatzki, C. Blumert, K. Bauer, H. Cvijic, A. K. Ullmann, P. F. Stadler, and F. Horn. 2007. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110, 1330-1333.   DOI
17 Studeny, M., F. C. Marini, J. L. Dembinski, C. Zompetta, M. Cabreira-Hansen, B. N. Bekele, R. E. Champlin, and M. Andreeff. 2004. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 96, 1593-1603.   DOI
18 Liu, Z. J., Y. Zhuge, and O. C. Velazquez. 2009. Trafficking and differentiation of mesenchymal stem cells. J. Cell Biochem. 106, 984-991.   DOI
19 Loeffler, M., J. A. Kruger, A. G. Niethammer, and R. A. Reisfeld. 2006. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J. Clin. Invest. 116, 1955-1962.   DOI   ScienceOn
20 Mi, H., Q. Dong, A. Muruganujan, P. Gaudet, S. Lewis, and P. D. Thomas. 2010. PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium. Nucleic Acids Res. 38, D204-210.   DOI
21 Micke, P. and A. Ostman. 2005. Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert. Opin. Ther. Targets 9, 1217-1233.   DOI
22 Ohlund, D., C. Lundin, B. Ardnor, M. Oman, P. Naredi, and M. Sund. 2009. Type IV collagen is a tumour stroma- derived biomarker for pancreas cancer. Br. J. Cancer 101, 91-97.   DOI
23 Orimo, A. and R. A. Weinberg. 2006. Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5, 1597-1601.   DOI
24 Kebriaei, P. and S. Robinson. 2011. Treatment of graft-versus- host-disease with mesenchymal stromal cells. Cytotherapy [Epub ahead of print].
25 Ostman, A. and M. Augsten. 2009. Cancer-associated fibroblasts and tumor growth--bystanders turning into key players. Curr. Opin. Genet. Dev. 19, 67-73.   DOI   ScienceOn
26 Patocs, A., L. Zhang, Y. Xu, F. Weber, T. Caldes, G. L. Mutter, P. Platzer, and C. Eng. 2007. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N. Engl. J. Med. 357, 2543-2551.   DOI
27 Kayamori, K., K. Sakamoto, T. Nakashima, H. Takayanagi, K. Morita, K. Omura, S. T. Nguyen, Y. Miki, T. Iimura, A. Himeno, T. Akashi, H. Yamada-Okabe, E. Ogata, and A. Yamaguchi. 2010. Roles of interleukin-6 and parathyroid hormone-related peptide in osteoclast formation associated with oral cancers: significance of interleukin-6 synthesized by stromal cells in response to cancer cells. Am. J. Pathol. 176, 968-980.   DOI
28 Khakoo, A. Y., S. Pati, S. A. Anderson, W. Reid, M. F. Elshal, I. I. Rovira, A. T. Nguyen, D. Malide, C. A. Combs, G. Hall, J. Zhang, M. Raffeld, T. B. Rogers, W. Stetler-Stevenson, J. A. Frank, M. Reitz, and T. Finkel. 2006. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 203, 1235-1247.   DOI
29 Kim, B. G., H. J. An, S. Kang, Y. P. Choi, M. Q. Gao, H. Park, and N. H. Cho. 2011. Laminin-332-rich tumor microenvironment for tumor invasion in the interface zone of breast cancer. Am. J. Pathol. 178, 373-381.   DOI
30 Lee, G. and M. Piquette-Miller. 2001. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can. J. Physiol. Pharmacol. 79, 876-884.   DOI
31 Lee, M. Y., J. M. Ryu, S. H. Lee, J. H. Park, and H. J. Han. 2010. Lipid rafts play an important role for maintenance of embryonic stem cell self-renewal. J. Lipid Res. 51, 2082-2089.   DOI
32 Dudley, A. C., S. C. Shih, A. R. Cliffe, K. Hida, and M. Klagsbrun. 2008. Attenuated p53 activation in tumour-associated stromal cells accompanies decreased sensitivity to etoposide and vincristine. Br. J. Cancer 99, 118-125.   DOI   ScienceOn
33 Lee, R. H., B. Kim, I. Choi, H. Kim, H. S. Choi, K. T. Suh, Y. C. Bae, and J. S. Jung. 2004. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell. Physiol. Biochem. 14, 311-324.   DOI
34 Legaspi, A., M. Jeevanandam, H. F. Starnes Jr, and M. F. Brennan. 1987. Whole body lipid and energy metabolism in the cancer patient. Metabolism 36, 958-963.   DOI
35 Dreuw, A., H. M. Hermanns, R. Heise, S. Joussen, F. Rodríguez, Y. Marquardt, F. Jugert, H. F. Merk, P. C. Heinrich, and J. M. Baron. 2005. Interleukin-6-type cytokines upregulate expression of multidrug resistance-associated proteins in NHEK and dermal fibroblasts. J. Invest. Dermatol. 124, 28-37.   DOI
36 Erdogan, M., A. Pozzi, N. Bhowmick, H. L. Moses, and R. Zent. 2008. Transforming growth factor-beta (TGF-beta) and TGF-beta-associated kinase 1 are required for R-Ras-mediated transformation of mammary epithelial cells. Cancer Res. 68, 6224-6231.   DOI
37 Franco, O. E., M. Jiang, D. W. Strand, J. Peacock, S. Fernandez, R. S. Jackson 2nd, M. P. Revelo, N. A. Bhowmick, and S. W. Hayward. 2011. Altered TGF-{beta} Signaling in a Subpopulation of Human Stromal Cells Promotes Prostatic Carcinogenesis. Cancer Res. [Epub ahead of print]
38 Gerlo, S., G. Haegeman, and W. Vanden Berghe. 2008. Transcriptional regulation of autocrine IL-6 expression in multiple myeloma cells. Cell Signal. 20, 1489-1496.   DOI
39 Giannelli, G. and S. Antonaci. 2000. Biological and clinical relevance of Laminin-5 in cancer. Clin. Exp. Metastasis. 18, 439-443.   DOI
40 Guo, S., M. Liu, and R. R. Gonzalez-Perez. 2010. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim. Biophys. Acta. 1815, 197-213.
41 Huang, da. W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4, 44-57.
42 Imamura, T., T. Manabe, G. Ohshio, Z. H. Wang, K. Yamaki, T. Yoshimura, H. Suwa, and M. Imamura. 1995. Immunohistochemical staining for type IV collagen and laminin in the stroma of human pancreatic cancer. Int. J. Pancreatol. 18, 95-99.
43 Bagley, R. G., W. Weber, C. Rouleau, M. Yao, N. Honma, S. Kataoka, I. Ishida, B. L. Roberts, and B. A. Teicher. 2009.Human mesenchymal stem cells from bone marrow express tumor endothelial and stromal markers. Int. J. Oncol. 34, 619-627.
44 Bergfeld, S. A. and Y. A. DeClerck. 2010. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev. 29, 249-261.   DOI
45 Blobe, G. C., P. S. William, and H. F. Lodish. 2002. Role of Transforming Growth Factor $\beta$ in Human Disease. N. Engl. J. Med. 342, 1350-1358.
46 Casas-Tinto, S., M. Gomez-Velazquez, B. Granadino, and P. Fernandez-Funez. 2008. FoxK mediates TGF-beta signalling during midgut differentiation in flies. J. Cell Biol. 183, 1049-1060.   DOI
47 Chen, W., W. Jin, N. Hardegen, K. J. Lei, L. Li, N. Marinos, G. McGrady, and S. M. Wahl. 2003. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886.   DOI
48 Chiarugi, V., L. Magnelli, and M. Cinelli. 1997. Complex interplay among apoptosis factors: RB, p53, E2F, TGF-beta, cell cycle inhibitors and the bcl2 gene family. Pharmacol. Res. 35, 257-261.   DOI
49 Colombo, M. P. and S. Piconese. 2007. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat. Rev. Cancer 7, 880-887.   DOI
50 Chou, Y. T., H. Wang, Y. Chen, D. Danielpour, and Y. C. Yang. 2006. Cited2 modulates TGF-beta-mediated upregulation of MMP9. Oncogene 25, 5547-5560.   DOI
51 Dennis, J. E. and P. Charbord. 2002. Origin and differentiation of human and murine stroma. Stem Cells 20, 205-214.   DOI   ScienceOn
52 Alhadlaq, A. and J. J. Mao. 2004. Mesenchymal stem cells: isolation and therapeutics. Stem Cell Dev. 13, 436-448.   DOI